Getinge (OTCMKTS:GNGBY) Upgraded at Zacks Research

Zacks Research upgraded shares of Getinge (OTCMKTS:GNGBY) from a hold rating to a strong-buy rating in a research note released on Tuesday morning,Zacks.com reports.

Getinge Price Performance

Shares of GNGBY opened at $23.41 on Tuesday. Getinge has a twelve month low of $18.99 and a twelve month high of $24.67. The company has a market capitalization of $6.38 billion, a P/E ratio of 22.30 and a beta of 0.96. The firm has a 50 day moving average of $20.94 and a 200 day moving average of $21.33. The company has a quick ratio of 0.86, a current ratio of 1.32 and a debt-to-equity ratio of 0.27.

Getinge (OTCMKTS:GNGBY) last released its quarterly earnings data on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. Getinge had a return on equity of 11.67% and a net margin of 7.81%.The business had revenue of $894.87 million for the quarter. As a group, equities research analysts anticipate that Getinge will post 1.38 earnings per share for the current fiscal year.

About Getinge

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.